New data presented at ASH 2018 from an ongoing phase I clinical trial of CAR T cell therapy in relapsed/refractory myeloma
Initial data from the ongoing phase I clinical trial of bb21217 (CRB-402) were presented at the 60th Annual Meeting of the American Society of Hematology (ASH). This is an investigational next-generation anti-BCMA CAR T cell therapy being studied in patients with relapsed/refractory myeloma.